Sino Biopharmaceutical : VOLUNTARY ANNOUNCEMENT - "BORTEZOMIB FOR INJECTION" OBTAINS APPROVAL OF DRUG SUPPLEMENTARY APPLICATION

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT

"BORTEZOMIB FOR INJECTION" OBTAINS APPROVAL OF

DRUG SUPPLEMENTARY APPLICATION

The board of directors (the "Board") of Sino Biopharmaceutical Limited (the "Company") announces that the anticancer drug "Bortezomib for Injection" (brand name "Yijiu"( 益久)) of Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., a subsidiary of the Company, has obtained the approval of drug supplementary application from the National Medical Products Administration of the People's Republic of China for the addition of certain specifications, including the addition of 1.0mg specification.

Bortezomib is a new anticancer drug in targeted therapy, being mainly used for treating multiple myeloma and mantle cell lymphoma. The Bortezomib for Injection developed by Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. was approved for launch in September 2018 (the then approved specification was 3.5mg); the approved additional specifications can provide patients with more options and better satisfy various market demands.

By order of the Board

Sino Biopharmaceutical Limited

Tse, Theresa Y Y

Chairwoman

Hong Kong, 16 December 2019

As at the date of this announcement, the Board comprises eight Executive Directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin and four Independent Non-Executive Directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong and Mr. Zhang Lu Fu.